Complication hémorragique inattendue pour un cancer bronchique sous double immunothérapie

[1]  N. Reguart,et al.  Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients. , 2018, Journal of thoracic disease.

[2]  Yun Fan,et al.  The efficacy and safety of anti‐PD‐1/PD‐L1 antibodies combined with chemotherapy or CTLA4 antibody as a first‐line treatment for advanced lung cancer , 2018, International journal of cancer.

[3]  J. Szustakowski,et al.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.

[4]  F. Hodi,et al.  Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management , 2018, Cancer.

[5]  O. Molinier,et al.  IFCT 1502-CLINIVO : efficacité et tolérance du nivolumab et du traitement post-nivolumab dans le cancer bronchique non à petites cellules au stade avancé. Une étude en vie réelle dans le cadre de l’ATU nivolumab 2015 , 2018 .

[6]  M. Socinski,et al.  LBA1_PRPrimary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150) , 2017 .

[7]  A. Bello,et al.  Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors , 2017, Journal of clinical pharmacology.

[8]  J. Mazières,et al.  Immunothérapie et cancer du poumon : où en sommes-nous ? , 2017 .

[9]  T. Self,et al.  Effect of diseases on response to vitamin K antagonists , 2016, Current medical research and opinion.

[10]  A. Anogeianaki,et al.  Effects of the Hormones of the Thyroid Axis on the Vitamin K-Dependent Plasma Factors of Blood Coagulation (II, VII, IX and X) , 2008, International journal of immunopathology and pharmacology.